Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression Sep 14, 2021
Mindset Pharma Further Validates Lead Candidate, MSP-1014, as a Next Generation Psilocybin Analog through Drug… Sep 14, 2021
Tim Schlidt of Palo Santo Discusses Why Psychedelics Therapy is the Future of End-of-Life Care Sep 13, 2021
PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022 Sep 13, 2021
